Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a partnership – worth up to $8 billion – that spans ...

Bayer has looked internally for a new chief medical officer, appointing Dr Christoph Koenen to the position in addition to ...

Eli Lilly's bid to dominate the next generation of weight-loss therapies has been strengthened by data on a new combination ...

Patients in England and Wales with rare disease familial chylomicronaemia syndrome (FCS) will soon have a new treatment ...

AbbVie's long-acting anti-IL-13 antibody zumilokibart – the main asset in its $10.9 billion takeover of Apogee Therapeutics – ...

Against this backdrop, the Leadership Summit will return to CPHI Milan in 2026, bringing senior pharmaceutical ...

The personalized cancer vaccine field has reached a defining milestone. With Moderna and Merck reporting positive initial ...

AZ's $2 billion investment – at $18.36 per share – puts the UK-headquartered company in the driving seat to pair its ...

Eli Lilly's triple G agonist retatrutide has achieved impressive weight loss in patients with type 2 diabetes and obesity, ...

Two Indian nationals are facing charges relating to the sale of counterfeit versions of Novo's diabetes treatment Ozempic to ...

Sustainability in Life Sciences Summit is the premier meeting point for sustainability, ESG, corporate responsibility, ...

The first product from AbbVie's $8.7 billion takeover of Cerevel two years ago – Parkinson's disease therapy tavapadon – has ...